Clinical Scenario

Goblet cell adenocarcinoma (GCA) of the appendix — also commonly referred to as goblet cell carcinoid — is a rare tumor type accounting for approximately 14 to 19% of primary appendix cancers. Unlike classic appendiceal neuroendocrine tumors, GCA behaves more like adenocarcinoma in its immunohistochemical profile and biologic behavior, which directly shapes the treatment approach.

Treatment Approach

For localized, primary appendiceal GCA, management centers on a surgical procedure aimed at achieving adequate oncologic control and pathologic staging, with particular attention to regional lymph node evaluation. The complete protocol specifies the procedure of choice, staging thresholds, and all associated criteria — see the full regimen for details.

References

DOI: 10.1055/s-0035-1564433

Goblet cell adenocarcinoma (GCA), also commonly referred to as "goblet cell carcinoid," is a rare tumor type accounting for approximately 14 to 19% of primary appendix cancers.
Recent studies have shown that GCAs are actually closer to adenocarcinoma than neuroendocrine carcinoma in terms of both immunohistochemical profile and biologic behavior.
In cases of localized, primary appendiceal GCA, lymph node involvement is present in 20 to 40% of cases, so right hemicolectomy is recommended for adequate treatment and staging regardless of primary tumor size.
As for colorectal adenocarcinoma, examination of at least 12 lymph nodes allows for optimal staging.

View source ↗

Treatment of Adenocarcinoma of Appendix in Goblet Cell Adenocarcinoma

References